<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001275</url>
  </required_header>
  <id_info>
    <org_study_id>910127</org_study_id>
    <secondary_id>91-CH-0127</secondary_id>
    <nct_id>NCT00001275</nct_id>
  </id_info>
  <brief_title>Ovarian Follicle Function in Patients With Primary Ovarian Failure</brief_title>
  <official_title>Ovarian Follicle Function in Patients With Primary Ovarian Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      No proven therapy to restore ovarian function and fertility is available to patients with&#xD;
      karyotypically normal spontaneous premature ovarian failure. We know that one-half of these&#xD;
      patients have primordial follicles remaining in the ovary, and these follicles can function&#xD;
      intermittently. This is a diagnostic omnibus protocol that permits baseline clinical&#xD;
      evaluation of patients with prematurem ovarian failure. The findings will determine patients'&#xD;
      suitability for specifically focused therapeutic research protocols.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No proven therapy to restore ovarian function and fertility is available to patients with&#xD;
      karyotypically normal spontaneous primary ovarian insufficiency. We know that more than&#xD;
      one-half of these patients have primordial follicles remaining in the ovary, and these&#xD;
      follicles can function intermittently. This protocol permitted baseline clinical evaluation&#xD;
      of patients with primary ovarian insufficiency and ongoing observation of the natural history&#xD;
      of the disorder. The protocol is now in the follow up and analysis phase and is not now&#xD;
      recruiting new patients. Now a major aim of the protocol is to investigate large scale&#xD;
      medical sequencing as a method by which to uncover mechanisms of primary ovarian&#xD;
      insufficiency and to assist in the management of women with this condition. This will involve&#xD;
      a community-based participatory research approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 12, 1991</start_date>
  <completion_date>February 8, 2017</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Actual">1134</enrollment>
  <condition>Amenorrhea</condition>
  <condition>Hypoaldosteronism</condition>
  <condition>Hypogonadism</condition>
  <condition>Infertility</condition>
  <condition>Premature Ovarian Failure</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Women 18 to 42 years of age with primary ovarian insufficiency who meet the following&#xD;
        requirements were candidates for recruitment to the study: 1) at least a four month history&#xD;
        of oligo-amenorrhea not due to pregnancy, and 2) clearly elevated gonadotropins in the&#xD;
        menopausal range on two separate occasions at least one month apart.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Women with evidence for karyotypic, metabolic, toxic, or iatrogenic cause of the ovarian&#xD;
        insufficiency were not candidates.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence M Nelson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, Shawker TH, Merino MJ. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab. 1994 Nov;79(5):1470-5. doi: 10.1210/jcem.79.5.7962345.</citation>
    <PMID>7962345</PMID>
  </reference>
  <reference>
    <citation>Anasti JN, Flack MR, Froehlich J, Nelson LM. The use of human recombinant gonadotropin receptors to search for immunoglobulin G-mediated premature ovarian failure. J Clin Endocrinol Metab. 1995 Mar;80(3):824-8. doi: 10.1210/jcem.80.3.7883837.</citation>
    <PMID>7883837</PMID>
  </reference>
  <reference>
    <citation>Kim TJ, Anasti JN, Flack MR, Kimzey LM, Defensor RA, Nelson LM. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1997 May;89(5 Pt 1):777-9. doi: 10.1016/s0029-7844(97)00077-x.</citation>
    <PMID>9166320</PMID>
  </reference>
  <verification_date>February 8, 2017</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Infertility</keyword>
  <keyword>Ovulation</keyword>
  <keyword>Amenorrhea</keyword>
  <keyword>Hypergonadotropic Hypogonadism</keyword>
  <keyword>Young Women</keyword>
  <keyword>Gonadal Steroid Deficiency</keyword>
  <keyword>Mineralocorticoid Deficiency</keyword>
  <keyword>Premature Ovarian Failure</keyword>
  <keyword>POF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Hypoaldosteronism</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

